Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+0.30%
$21.52
88% positive prob.
5-Day Prediction
+6.39%
$22.83
88% positive prob.
20-Day Prediction
+2.68%
$22.03
83% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +0.30% | +6.39% | +2.68% | 75.3% | Pending |
| Q2 2026 | SELL | -2.89% | -7.58% | +4.98% | 100.0% | Pending |
| Q1 2026 | BUY | +0.15% | +8.89% | +6.92% | 100.0% | +2.15% |
| Q4 2025 | BUY | +0.15% | +8.89% | +6.92% | 100.0% | -7.80% |
SEC 8-K filings with transcript text
Nov 9, 2026 · 75% conf.
1D
+0.30%
$21.52
Act: +1.21%
5D
+6.39%
$22.83
20D
+2.68%
$22.03
2 tm2629207d1_ex99-1.htm
Exhibit 99.1
Structure Therapeutics Reports Third Quarter 2026 Financial Results
and Recent Highlights
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of
aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling;
topline data expected in 2H 2028
Additional aleniglipron data expected in Q4 2026
from supplementary body composition, type 2 diabetes and SWITCH studies
Reported Phase 1 SAD data for ACCG-2671 (oral small molecule amylin receptor agonist),
demonstrating a ~6-day half-life and no serious adverse events;
MAD clinical trial dosing underway, with topline data expected in 1H 2027
Cash, cash equivalents and short-term investments of $1.2 billion as of September 30, 2026
expected to fund projected operations and key clinical milestones through 2028
SAN FRANCISCO, November 9, 2026 (GLOBE NEWSWIRE) – Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2026, and provided a business update across its oral small molecule obesity portfolio.
“With our Phase 3 ACCOMPLISH program underway, we are advancing aleniglipron toward potential registration while building a broader portfolio of differentiated oral small molecule treatments for chronic weight management,” said Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics. “We are developing our commercial readiness plans and see significant opportunity for aleniglipron in both initial weight loss and long-term weight loss maintenance.”
Dr. Stevens continued, “We are also advancing our oral small molecule amylin portfolio by progressing the multiple ascending dose clinical trial of ACCG-2671, preparing to initiate a Phase 1 clinical trial of ACCG-3535 and exploring GLP-1 combination approaches. Our strategy is to develop differentiated monotherapy and combination medicines to address a range of patient needs. We believe convenient oral administration and scalable manufacturing could help expand access to these potential treatments globally.”
Recent and Upcoming Milestones
Aleniglipron – Oral Small Molecule Selective Glucagon-Like
Peptide 1 (GLP-1) Receptor Agonist
The Phase 3 ACCOMPLISH program, which initiated in August 2026, comprises two randomized, double-blind, placebo-controlled clinical trials designed to evaluate the long-term efficacy and safety of aleniglipron and to support global regulatory submissions for chronic weight management.
·ACCOMPLISH-1 is enrolling up to 3,600 adults living with obesity or overweight with at least one weight-related comorbidity. ACCOMPLISH-2 is enrolling up to 1,100 adults living with obesity or overweight and type 2 diabetes mellitus (T2DM).
·In both trials, participants will receive placebo or one of three aleniglipron maintenance doses (45 mg, 90 mg or 180 mg) following a 2.5 mg starting dose and dose escalation at four-week intervals. Topline data are expected in the second half of 2028.
In September 2026, the Company reported 72-week results from the ACCESS open-label extension (OLE), a prespecified 36-week extension of the Phase 2b ACCESS clinical trial designed to evaluate the longer-term safety and tolerability of aleniglipron and the durability of weight loss through 72 weeks of treatment. Participants originally randomized to the 45 mg, 90 mg and 120 mg arms in ACCESS who continued into the OLE dosed up to 180 mg. Data demonstrated up to 16.2% mean reduction in body weight in the highest dose group at 72 weeks with no observed plateau in the two top dose groups, and improved tolerability with a 2.5 mg starting dose, including treatment discontinuation rates of less than 5% due to treatment-emergent adverse events.
The Company will present two posters on aleniglipron at The Obesity Society’s Annual Meeting, ObesityWeek® 2026, taking place November 14–17, 2026, in National Harbor, Maryland. The presentations will cover the ACCESS OLE and the dose-ranging effects of aleniglipron across the ACCESS trials. Both posters are scheduled for presentation on November 15, 2026.
Additional aleniglipron data expected in the fourth quarter of 2026 include topline results from three supplementary clinical trials designed to build on the Phase 2 findings and further characterize aleniglipron’s clinical profile:
·Body composition clinical trial: Results from a 44-week study evaluating the effects of aleniglipron on body fat and overall body composition.
·T2DM clinical trial: Results from a 30-week study in adults living with T2DM and obesity or overweight.
·SWITCH clinical trial: Results evaluating the transition from an approved injectable GLP-1 receptor agonist to once-daily oral aleniglipron for weight loss maintenance. This study assesses different aleniglipron starting doses and weight loss main
Aug 6, 2026 · 100% conf.
1D
-2.89%
$51.10
Act: +0.99%
5D
-7.58%
$48.63
20D
+4.98%
$55.24
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1786284862.ba8f85f5
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
May 7, 2026 · 100% conf.
1D
+0.15%
$39.06
Act: +0.04%
5D
+8.89%
$42.47
Act: +2.15%
20D
+6.92%
$41.70
Act: -3.64%
4 tm2613721d1_ex99-1.htm
Exhibit 99.1
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Reported positive results from aleniglipron Phase 2 ACCESS II study
with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs
at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs
Data from ACCESS OLE expected in Q3 2026;
Data from the Body Composition and Type 2 Diabetes / Obesity data expected in Q4 2026
Positive end-of-Phase 2 feedback received from FDA;
aleniglipron Phase 3 initiation on track for Q3 2026
Initial data from Phase 1 single ascending dose (SAD) study of oral small molecule amylin
receptor agonist ACCG-2671 and initiation of multiple ascending dose (MAD) study expected in
Q3 2026; Phase 1 initiation of second oral amylin candidate ACCG-3535 expected in Q4 2026
Aleniglipron, amylin and combination data to be presented
at the American Diabetes Association (ADA) 86th Scientific Sessions in June 2026
Cash, cash equivalents and short-term investments of $1.5 billion as of March 31, 2026,
expected to provide cash runway through the end of 2028
SAN FRANCISCO, May 7, 2026– Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
“With positive end of Phase 2 feedback received from the FDA for aleniglipron, we are well positioned to start our Phase 3 registrational program for chronic weight management in the third quarter,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “We are also looking forward to our aleniglipron
1 clinical data for our oral amylin candidate ACCG-2671 anticipated in the third quarter and additional aleniglipron data later this year, our broad portfolio positions us well in the evolving landscape that we believe will favor more accessible oral small molecules, extended maintenance treatment, and fixed dose oral combinations for specific patient populations and expanded indications.”
Recent and Upcoming Milestones
Aleniglipron - Oral Small Molecule
Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight
In March 2026, the Company reported data from the aleniglipron clinical program included 44-week topline data from the Phase 2 ACCESS II study, as well as interim data from body composition study and Phase 2b ACCESS open label extension (OLE) study.
· The Phase 2 ACCESS II study demonstrated a placebo-adjusted mean weight loss of 16.3% (39 Ibs; p<0.0001) at the 180 mg dose and 16.0% (37 Ibs; p<0.0001) at the 240 mg dose at 44 weeks.
· The ongoing ACCESS OLE study achieved continued weight loss up to 16.2% (40.5 lbs) observed with 120 mg dose at 56 weeks.
· No weight loss plateau was observed in any of the studies.
Data from the ACCESS, ACCESS II, Body Composition, and the ACCESS OLE studies provide a strong foundation for the decision to advance aleniglipron into Phase 3 clinical development. The Company expects to report topline results from the ACCESS OLE and Body Composition studies in Q3 and Q4 2026, respectively.
The Company received positive end-of-Phase
2 feedback from the U.S. Food and Drug Administration (FDA) and clear guidance on the Phase 3 program with a starting titration dose of 2.5 mg and the intent to evaluate multiple doses. The Company anticipates initiating the Phase 3 program in Q3 2026.
The Company is also conducting supplementary studies to enhance the competitive profile of aleniglipron, including:
· Ongoing study of ACCESS OLE to evaluate the tolerability profile of the dosing regimen starting at the 2.5 mg dose for those previously on placebo and to collect up to 72 weeks of data exposure to aleniglipron, including 180 mg dose. Data are expected in Q3 2026.
· Ongoing Body Composition study to assess the effect of aleniglipron on body fat loss over a 44-week evaluation period, which includes a 28-week titration period and a starting dose of 2.5 mg and target dose of 180 mg of aleniglipron. These data will be used to inform the size of a sub study into the Phase 3 program. Data are expected in Q4 2026.
· Ongoing 30-week study in patients with type 2 diabetes mellitus (T2DM) with obesity/overweight and a starting dose of 2.5 mg and target dose of 180 mg of aleniglipron to evaluate the potential for including participants with T2DM in the Phase 3 obesity program. Data are expected in Q4 2026.
· Ongoing SWITCH study to assess the transition or switching from an approved injectable GLP-1 receptor agonist to once-daily oral aleniglipron for weight loss maintenance. This study assesses different alen
This page provides Structure Therapeutics Inc. (GPCR) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on GPCR's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.